Adagene
Update in progressADAG (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Adagene Inc. is a clinical‑stage biotechnology company focused on monoclonal antibody drugs for cancer in China. Its lead candidate, ADG126, is a masked, fully human anti‑CTLA‑4 mAb in phase 1b/2. Other programs include ADG116 (anti‑CTLA‑4, phase 1b/2), ADG206 (phase 1), ADG104 (anti‑PD‑L1, phase 2), and ADG125 (anti‑CSF‑1R, phase 2). Preclinical: ADG138 (HER2xCD3 POWERbody), ADG152 (CD20xCD3), ADG153 (masked anti‑CD47 SAFEbody), and CD28 T‑cell engagers. Founded 2011, based in Suzhou.
Company score
- Sentiment
- 0.38
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.18
- Governance
- 0.17
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.24
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationChina
- CEODr. Peter P. Luo Ph.D.
- Founded2011
- Employees128
- Websitewww.adagene.com
Identifiers
- ISINUS0053291078
- FIGIBBG00YZ6BYJ6
- CUSIP005329107
- CIK0001818838